I just watched it. Must say the new management seems to be doing the right thing compare to the previous one. At least now SUNZEN is no longer losing money but making profit
As consumers pay more and more attention to preventive health care and natural remedies, Sunzen's traditional Chinese medicine and human health supplement products have huge growth potential
Sunzen Biotech eyes bigger share of China bird’s nest market. Sunzen subsidiary Ecolite Biotech Manufacturing Sdn Bhd has received approval from China’s customs authority in October last year to export its bottled bird’s nest to the country up to 2028.
The demand for edible bird’s nest products is indeed strong in China, Hong Kong, and other parts of Southeast Asia. The Chinese market, in particular, is one of the largest consumers of bird’s nests, driven by a cultural preference for traditional health products and rising disposable incomes
Sunzen's loan financing business is expected to continue to grow given the increasing trend in the number of applications and approvals, mainly due to our ability to provide fast and efficient services and structure more flexible loan packages to meet the needs of the SME market.
Acquisition of Eye Nation Medical is expected to contribute positively to the future financial performance of the Sunzen group, enhancing the group’s revenue and profitability, as it is secured by a profit guarantee of an audited profit after tax of RM2.60 million over the next two financial years
QR was out, the company reported revenue of RM22.96 million and PBT of RM0.86 million. In the current quarter, human health products and loan financing accounted for 76.85% and 14.26%, respectively, while the remaining 8.89% came from the animal health business.
Malaysia is one of the world’s largest producers of bird’s nest, with a significant portion of its production exported to China, where demand remains robust. Maintain a "buy" rating on Sunzen
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
gloveshapiro
18 posts
Posted by gloveshapiro > 2024-08-08 15:07 | Report Abuse
0.31-0.32 is a steady & cheap entry price now, Sunzen entering the healthcare sector will push the price further up